AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Paramount-Warner Bros. Merger Delayed Until 2027 Amid Antitrust Lawsuit 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum 
Coca-Cola Raises Diet Coke Prices in India as Iran Conflict Disrupts Can Supply 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
SpaceX Stock Slump Wipes Out Nearly $700 Billion From Elon Musk’s Paper Wealth 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Shein Reports $99 Million Loss Ahead of Hong Kong IPO as U.S. Tariffs Hit Sales 
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
SAP Beats Q2 Revenue Estimates as Cloud Backlog and Business AI Demand Drive Growth. 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
When it comes to the red-hot sector of psychedelics, there’s no shortage of companies looking to enter the market. Quantity over quality can be an issue for any new industry, with hundreds of companies scrambling to stake their claim. However, it appears that a leader has emerged in the field. According to a recent survey by StrawPoll, Denver based Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) ranks as the “favourite” publicly traded company in the psychedelic sector.
This comes as no surprise following Mydecine’s recent landmark progress in psychedelic research across the board. This year has been an important one for the company after successfully completing the first legal import of psychedelic mushrooms to Canada. This marks a major first step in the creation of a comprehensive psychedelic supply chain. In addition to Mydecine’s import capabilities, the company has announced an upcoming clinical trial to study the use of psychedelics in the treatment of PTSD. The first-of-its-kind clinical trial is a major step in the company’s goals to revolutionize the treatment of mental health and wellbeing. These trials are global in scope, with research taking place in 7 countries around the world.
Beyond clinical research and design, Mydecine is also innovating in the world of tech, with the creation of a remote mental health service delivery platform called “Mindleap''. It appears the company has effectively diversified and Mydecine’s CEO, Josh Bartch, attributes their recent success to this diverse set of capabilities.
“One thing about Mydecine that’s incredibly unique is that we’re fully vertically integrated, so as it pertains to psychedelic assisted psychotherapy, we really have an A-Z capability.”
Mydecine is quickly becoming the all-in-one brand in the space of psychedelics. With a recent uplisting to the NEO stock exchange, this novel industry leader has significant potential and will be one to watch moving forward.
This article does not necessarily reflect the opinions of the editors or the management of EconoTimes.
